D. E. Shaw & Co., Inc. Repligen Corp Put Options Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$119.79 - $167.35 $598,950 - $836,750	5,000 Added 25.0%	25,000 $3.72 Million
Q2 2024 Aug 14, 2024	BUY	$120.0 - $182.95 $2.4 Million - $3.66 Million	20,000 New	20,000 $2.52 Million
Q2 2023 Aug 14, 2023	BUY	$138.42 - $180.31 $1.45 Million - $1.89 Million	10,500 Added 233.33%	15,000 $2.12 Million
Q1 2023 May 15, 2023	SELL	$154.26 - $198.1 $1.16 Million - $1.49 Million	-7,500 Reduced 62.5%	4,500 $757,000
Q4 2022 Feb 14, 2023	SELL	$162.42 - $220.56 $2.68 Million - $3.64 Million	-16,500 Reduced 57.89%	12,000 $2.03 Million
Q3 2022 Nov 14, 2022	SELL	$160.42 - $256.21 $770,015 - $1.23 Million	-4,800 Reduced 14.41%	28,500 $5.33 Million
Q2 2022 Aug 15, 2022	BUY	$140.68 - $188.02 $1.04 Million - $1.39 Million	7,400 Added 28.57%	33,300 $5.41 Million
Q1 2022 May 16, 2022	BUY	$161.19 - $257.96 $1.9 Million - $3.04 Million	11,800 Added 83.69%	25,900 $4.87 Million
Q4 2021 Feb 14, 2022	BUY	$247.59 - $304.47 $3.22 Million - $3.96 Million	13,000 Added 1181.82%	14,100 $3.73 Million
Q3 2021 Nov 15, 2021	BUY	$194.77 - $324.21 $214,247 - $356,631	1,100 New	1,100 $318,000

487

54.4M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $6.92B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.